You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Dual Molecular/Targeting Therapy for PanCa
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic Cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of chem ...
STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health -
A Dual Molecular/Tumor Targeting Therapy for PanCa
SBC: SYNERGENE THERAPEUTICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Approximately 30,000 people in the United States are diagnosed each year with pancreatic cancer (PanCa). Over 90% of these will die of the disease making PanCa one of the most devastating human malignancies. The current 5-year survival rate of less than 4% has changed little in the last 20 years despite improvements in therapy including the introduction of ...
STTR Phase II 2004 Department of Health and Human ServicesNational Institutes of Health -
A Global Test of Hemostatic Risk
SBC: Haematologic Technologies, LLC Topic: N/ADESCRIPTION (provided by applicant): Although the vast majority of patients who suffer from venous or arterial thrombosis have haemostatic systems that fall within the "normal" range of routine screening tools such as PT, aPTT, and factor assays, thrombosis is the major cause of death in Western countries. In contrast, the propensity to bleed (i.e., hemophilia) is more easily diagnosed by traditio ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
A Global Test of Hemostatic Risk
SBC: Haematologic Technologies, LLC Topic: N/ADESCRIPTION (provided by applicant): Phase I funding for this project supported successful studies that were aimed at demonstrating the feasibility of developing an easy to use, global test in the arena of clinical hemostasis that would be sensitive to antithrombotic drugs, bleeding disorders and thrombotic pathologies. This test comprises a measurement of the rate of thrombin generation and/or to ...
STTR Phase II 2007 Department of Health and Human ServicesNational Institutes of Health -
Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis
SBC: Generx+, Inc. Topic: N/ADESCRIPTION (Applicant's Abstract): The investigators have developed a plasmid vector that expresses the normal human alpha-1 antitrypsin (AAT) gene in human respiratory epithelium when delivered as a plasmid-cationic liposome complex. In subjects with inherited AAT deficiency, they showed that liposome mediated transfer of the normal AAT gene to the nasal respiratory epi ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy
SBC: Praetego Inc Topic: NEIPROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
AML MutationCounter a tool to detect residual and recurrent leukemia
SBC: Asystbio Laboratories, LLC Topic: 102Abstract AsystBio LLC proposes to market a molecular tool kit called AML MutationCounter to count somatic mutations in genes that contribute to the development of acute myeloid leukemia AML We have developed a set of reagents and computer programs for application of next generation sequencing to count AML gene mutations The tool kit is versatile and can be used with either of the two major DNA ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A momentum-enabled treadling methodology to improve gait and enhance mobility in patients with peripheral arterial disease
SBC: TREADWELL CORPORATION Topic: NIAProject SummaryA significant cause of mobility impairment in the elderly is peripheral arterial diseasePADPAD results in significant functional declinereduced walking speed and distanceand lower physical activity levelsresulting in a loss of independence and impaired quality of lifeThe most effective therapy for PAD is rigorous exercisee gwalkingHowevermost PAD patients will not participate in sup ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
An Advanced Biosensor for Molecular Interaction Studies
SBC: MOLECULAR SENSING, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Molecular interactions are central to the understanding of basic biology and cellular function, are paramount to all molecular assays (research and in vitro diagnostics), are essential in biomarker discovery and critical toward evaluating therapeutics. However, the tools available to quantify these interactions have limitations, in so far as they either rely up ...
STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
An Advanced Biosensor for Molecular Interaction Studies.
SBC: MOLECULAR SENSING, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health